Based on our findings, it is possible that co-administration of inhibitors of MEK, PI3K, mTOR, IDH1, EZH2 or CDK4/6 (to target CDKN2A deletion) may have been effective in slowing or reducing tumour progression [52,68,81,82,83,84,85]. The gene discussed is MAP2K7; the disease is neoplasm.